Moloney Securities Asset Management LLC Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Moloney Securities Asset Management LLC increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 40.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,547 shares of the medical research company's stock after buying an additional 1,028 shares during the quarter. Moloney Securities Asset Management LLC's holdings in Thermo Fisher Scientific were worth $1,765,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. LBP AM SA boosted its holdings in shares of Thermo Fisher Scientific by 43.3% during the 1st quarter. LBP AM SA now owns 230,201 shares of the medical research company's stock valued at $114,548,000 after buying an additional 69,507 shares in the last quarter. Axxcess Wealth Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 8.3% during the 1st quarter. Axxcess Wealth Management LLC now owns 23,748 shares of the medical research company's stock valued at $11,817,000 after buying an additional 1,823 shares in the last quarter. Rehmann Capital Advisory Group boosted its stake in Thermo Fisher Scientific by 1.7% in the 1st quarter. Rehmann Capital Advisory Group now owns 2,447 shares of the medical research company's stock worth $1,218,000 after purchasing an additional 42 shares in the last quarter. Cornerstone Planning Group LLC boosted its stake in Thermo Fisher Scientific by 105.0% in the 1st quarter. Cornerstone Planning Group LLC now owns 123 shares of the medical research company's stock worth $61,000 after purchasing an additional 63 shares in the last quarter. Finally, Brick & Kyle Associates boosted its stake in Thermo Fisher Scientific by 0.3% in the 1st quarter. Brick & Kyle Associates now owns 9,868 shares of the medical research company's stock worth $4,828,000 after purchasing an additional 30 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president owned 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

TMO has been the subject of several research reports. Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. UBS Group lowered shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and reduced their price target for the company from $500.00 to $460.00 in a research report on Tuesday. Barclays reduced their price target on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a research report on Tuesday, June 24th. Royal Bank Of Canada reduced their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $600.30.

Thermo Fisher Scientific Stock Up 1.0%

Shares of Thermo Fisher Scientific stock traded up $4.29 during trading on Friday, hitting $435.02. 2,511,384 shares of the stock traded hands, compared to its average volume of 1,993,056. The firm has a market cap of $164.22 billion, a P/E ratio of 25.51, a price-to-earnings-growth ratio of 2.23 and a beta of 0.77. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The stock's fifty day simple moving average is $409.16 and its 200 day simple moving average is $477.24.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business's revenue for the quarter was up .2% on a year-over-year basis. During the same quarter last year, the firm posted $5.11 earnings per share. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.40%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.